Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review

Table 2 Bevacizumab with oxaliplatin-based chemo-radiotherapy: Overview of the discussed studies

Ref.	Phase	n	Treatment	Stage	Post-operative complications (n)	pCR
Czito et al[18], 2007	I	11	BV 15 mg/kg and 10 mg/kg, CAPE 625 mg/m2bid, oxaliplatin 50 mg/m2 weekly, RT 50.4 Gy in 28 fr.	II-III	Abscess (1)	18%
Dellas et al[19], 2013	II	70	BV 5 mg/kg, CAPE 825 mg/m2bid, oxaliplatin 50 mg/m2 weekly, RT 50.4 Gy in 28 fr.	II-III-IV	Anal fistula (1)	17.4%
					Pelvic abscess (1)
					Delayed wound healing (1)
Kennecke et al[20], 2012	II	42	BV 5 mg/kg, CAPE 825 mg/m2bid, oxaliplatin 50 mg/m2 weekly, RT 50.4 Gy in 28 fr.	II-III-IV	Pelvic infection (11)	18.4%
					Delayed healing (7)
					Anastomotic leak (6)
					Fistula (3)
Landry et al[21], 2013	II	57	BV 5 mg/kg, CAPE 825 mg/m2bid, oxaliplatin 50 mg/m2 weekly, RT 50.4 Gy in 28 fr. (+ post-operative FOLFOX + BV)	II-III	Early complications:	17%
					Wound infection (8)
					Fascial dehiscence (5)
					Intra-abdominal abscess (1)
					Fistula (1)
					Bowel obstruction (1)
					Thromboembolism (1)
					Late complications:
					Wound infection (23)
					Wound/fascial dehiscence (12)
					Bowel obstruction/ileus (5)
					Intra-abdominal abscess (2)
					Anastomotic leak (1)

CT-RT: Chemo-radiotherapy; BV: Bevacizumab; RT: Radiotherapy; CAPE: Capecitabine; fr.: Fractions; FOLFOX: 5-fluorouracil and oxaliplatin; pCR: Pathological complete response.